Objective: Although type 2 diabetes is recognized as an independent risk factor for cardiovascular disease and cardiovascular disease is associated with endothelial dysfunction, the influence of type 2 diabetes per se on the endothelial function is controversial. HMG-CoAreductase inhibitors have been shown to have short-term beneficial effects on endothelial dysfunction among patients with dyslipidemia or cardiovascular disease. The effect of HMG-CoA reductase inhibitors on the endothelial function in diabetes is largely unknown. Methods: Seventeen patients with type 2 diabetes, free of cardiovascular disease and no other cardiovascular risk factors, except for dyslipidemia, were studied together with ten healthy volunteers. The effect of 5-hydroxytryptamine, as an endothelium-dependent vasodilator, and sodium nitroprusside, as an endothelium-independent vasodilator, on the forearm blood flow was measured using venous occlusion plethysmography. Results: 5-Hydroxytryptamine and sodium nitroprusside, infused in the brachial artery, caused a dose-dependent vasodilation. The vasodilator response to 5-hydroxytryptamine was significantly lower among the diabetic patients, 42 and 56%, than among the controls, 73 and 103%, at a dose of 0.3 and 0.9 ng / kg / min, respectively (P,0.05 and P,0.001). Vasodilator responses to sodium nitroprusside were comparable among the diabetic patients and controls. A 6-week treatment with simvastatin 40 mg once daily did not change the vasodilator responses to 5-hydroxytryptamine or sodium nitroprusside among the patients with diabetes.
Introduction
The endothelial dysfunction has been proven to be a predictor for future cardiovascular events [1, 2] . Acute Cardiovascular disease is an important main long-term hyperglycemia and acute hyperinsulinemia tested in clamp complication of type 2 diabetes mellitus (DM 2), causing a studies have been found to impair the endothelial function two-to four-fold increase in cardiovascular mortality and in healthy subjects [3, 4] . In contrast, contradictory results morbidity. DM 2 is recognized as an independent risk have been reported about whether or not the endothelial factor for cardiovascular disease, however, most patients function is impaired among patients with chronic hyhave a combination of cardiovascular disease risk factors, perglycemia and hyperinsulinemia, i.e. patients with DM 2 such as obesity, hypertension, and dyslipidemia, all contri- [5] [6] [7] [8] [9] [10] . Furthermore, the presence of other cardiovascular buting to the increased risk for these patients.
risk factors and autonomic neuropathy may hamper the interpretation of these studies. Restoration of the impaired endothelial function has been shown in patients with eat one slice of white bread. Patients on oral medication dyslipidemia after 4-6 weeks of statin treatment [11, 12] .
did not take any medication until after the examination, To evaluate whether the chronic disturbed glucose patients on insulin received half their morning dose. metabolism in DM 2 causes endothelial dysfunction and to elucidate the role of dyslipidemia a study was performed 2.3. Drugs and solutions on endothelial function in patients with DM 2 and on the lipid levels in the range from normal to the typical diabetic
The following compounds were used for intra-arterial dyslipidemia. Second, to evaluate whether the possible infusion: 5-hydroxytryptamine (5HT; ICN Biomedicals, disturbance in the endothelial function was reversed by OH, USA), and sodium nitroprusside (SNP; Merck, Darmstatin therapy, we treated the DM 2 patients with simvasstadt, Germany). 5HT was dissolved in 0.9% saline, and tatin 40 mg daily for 6 weeks.
SNP was dissolved in 5% glucose. 5HT was used because it is a specific stimulator of endothelium-dependent, NOmediated, vasodilation, in contrast to acetylcholine which 2. Methods has alternative pathways to induce vasodilation, i.e. via stimulating endothelial derived hyperpolarizing factor [18].
Subjects
On the day of the study the solutions were prepared from sterile stock solutions and ampoules and stored at 48C until Seventeen male patients with DM 2 were recruited. Ten use. Merck Sharp and Dohme (Haarlem, The Netherlands) healthy middle-aged male volunteers (controls) participated kindly provided simvastatin tablets of 40 mg. in the study. All patients were free of hypertension, nonsmoking, younger than 65 years of age and free of 2.4. Study protocol symptoms or signs of cardiovascular disease. DM 2 patients with HbA1c levels above 8.5% were excluded.
2.4.1. Study day 1 The presence of autonomic neuropathy was excluded using A fasting venous blood sample was drawn for measurethe methods of cardiac rhythm variability, the Ewing test ments of serum lipids. The endothelium-dependent vasodiand the deep breathing test, and the orthostatic blood lation in both patients with DM 2 and in the controls was pressure test [13] . Patients with overt diabetic nephropathy measured using intra-arterial cumulative-dose infusions of were excluded, in 16 of the diabetic cases the albumin / 5HT (0.3 and 0.9 ng / kg / min). SNP (30 and 90 ng / kg / creatinine ratio was below 2.5 mg / mmol in a morning min), a direct nitric oxide donor, was infused as an urine portion while one diabetic patient had microalendothelium-independent vasodilator. Doses were chosen buminuria as measured in a timed urine portion; all in the steep part of the dose response curve, without patients had a plasma creatinine level below the upper inducing dilation of the venous vascular bed [19] . The limit of normal (,133 mmol / l). Patients using lipid drugs were given in random order and each dose step was lowering medication were excluded. Female subjects were administered by means of intra-arterial infusion for 7 min. not included because of possible influences of female A washout period of 15 min was applied between the hormones on the vascular wall. All patients signed a different infusions in order to allow forearm blood flow to written informed consent. The Medical Ethics Committee return to baseline levels. FBF, blood pressure, and heart of the Leiden University Medical Center approved the rate were measured during the 2 min prior to the start of study protocol. This investigation was carried out accordeach intra-arterial infusion, and during the last 2 min of ing to the principles outlined in the Declaration of Helsinki each infusion step. FBF is measured as ml / 100 ml forearm [14] .
tissue / min. Vasodilator responses caused by the infusions of 5HT and SNP are expressed as percentage change from 2.2. Procedures baseline FBF.
Blood samples were drawn after 12 h of fasting and 2.4.2. Study day 2 measured according to standardized laboratory protocols.
The experiments of study day 1 were repeated among A morning urine portion was collected for measurement of the patients with DM 2 after a treatment of 6 weeks with the albumin / creatinine ratio.
40 mg of simvastatin administered once daily. Drug Forearm blood flow (FBF) was measured by comcompliance was measured by counting the number of puterized, R-wave triggered, venous occlusion plethysmogtablets returned. raphy, using mercury in silastic strain gauges and a rapid cuff inflator (Hokanson Inc., Bellevue, USA) as described 2.5. Statistics previously [15] [16] [17] . Blood glucose was measured 1 min before each new vasoactive compound using a finger stick Continuous variables were expressed as mean6S.E.M. 
dent's t-test. Differences in vasodilator responses were
The local intra-arterial infusions of 5HT and SNP did tested for significance using Student's t-test and ANOVA.
not induce any significant changes in intra-arterial blood The actual blood glucose, total cholesterol, LDL-cholespressure and heart rate. Therefore, the changes in FBF can terol (LDL-c), HDL-cholesterol (HDL-c) and triglycerides be interpreted as true local vascular effects of the vasoacwere added as covariates to evaluate their influence on tive drugs used [15, 16] . No differences were found in forearm blood flow responses. The effects of simvastatin baseline FBF of the randomly chosen first and second drug therapy on lipoprotein profiles were analysed using the used, nor were differences found between baseline FBF of Student's t-test. Statistical significance was accepted at the the two different vasoactive drugs, so the initial 15 min 5% level. The statistical analyses were performed with and the 15 min of wash-out were long enough for SPSS / PC1E software (SPSS Inc, Chicago, IL, USA).
acclimatisation to the experimental procedure and achieving a stable non-stressed baseline. Even after corrections for actual blood glucose, total cholesterol, LDL-c, HDL-c 3. Results or triglycerides the outcome of the study did not change. No significant correlation was found between the actual The baseline characteristics of the study groups are blood glucose levels and the FBF responses. No side listed in Table 1 . As expected, fasting glucose was effects were reported throughout the study. significantly higher in the patients with DM 2, in addition the DM 2 patients were more obese. The patients with DM 3.1. Study day 1 2 had a higher mean level of serum triglycerides, while total cholesterol, LDL-c and HDL-c levels showed no
In DM 2 the cumulative intra-arterial infusion of 5HT difference. According to the inclusion criteria none of the 0.3 and 0.9 ng / kg / min induced a dose-dependent increase patients showed any evidence of overt nephropathy or in FBF of 4266.4 and 5667.2%, respectively (P50.01). autonomic neuropathy. The kind of treatment for glucose
In the control group this cumulative dose-infusion of 5HT control of patients with DM 2 is given in Table 1 . None of elicited an increase in FBF of 73612.0 and 103610.0%, the patients used aspirin, folic acid or blood pressure respectively (P50.033), which is significantly higher lowering medication. No changes in medication or dosage compared to the responses in the DM 2 group (P50.018 were made throughout the study.
for the low dose and P50.001 for the high dose) (Fig. 1) . The forearm vascular responses to intra-arterially infused SNP 30 and 90 ng / kg / min were similar in both groups, dian 1.80 mmol / l), with a p value ,0.001. The HDL-c causing a significant dose-dependent increase in FBF of increased significantly from 1.0460.071 mmol / l (median 178623.1 and 292641.0% in the DM 2 group, and of 1.00 mmol / l) to 1.1060.066 mmol / l (median 1.10 mmol / 218622.4 and 348642.1% in the control group (P,0.001 l), with a p value of 0.01. No significant change of the for both) (Fig. 1) .
triglyceride level was found, from 2.960.70 mmol / l (median 1.66 mmol / l) to 2.260.39 mmol / l (median 1.63 3.2. Study day 2 mmol / l). To investigate whether the forearm vascular responses On average 96% (range 83-100%) of the simvastatin were dependent on lipid levels, the patients with DM 2 tablets were taken. No changes in fasting glucose were were divided in two groups based on lipid levels below found and no clinical or biochemical side effects were and above the median levels in this group on study day 1. observed. Among the patients with DM 2 the vasodilator The vasodilator responses on study day 1 to both 5HT and responses to 5HT and SNP did not change after 6 weeks of SNP were not significantly different in the DM 2 patients treatment with simvastatin 40 mg compared to the rewith lipid levels above median compared to the DM 2 sponses before treatment on study day 1, as shown in Fig. patients below the median. The vasodilator responses 2. During treatment with simvastatin, 5HT 0.3 and 0.9 during treatment with simvastatin (study day 2) were not ng / kg / min increased the FBF with 3864.2 and 6067.5%, significantly different between the DM 2 patients achieving respectively (P50.001). SNP 30 and 90 ng / kg / min inbelow median versus above median lipid levels. creased the FBF with 163617.2 and 269628.7%, respectively (P,0.001). The lipid lowering effect of simvastatin 40 mg for 6 weeks in the patients with DM 2 resulted in a significant reduction of the total cholesterol levels from 4. Discussion 5.760.28 mmol / l (median 5.5 mmol / l) to 3.960.21 mmol / l (median 1.63 mmol / l), with a p value ,0.001.
In the present study a significant impairment of the The LDL-c was significantly lowered from 3.460. 26 endothelial function was found in patients with DM 2, mmol / l (median 3.4 mmol / l) to 1.9660.14 mmol / l (meusing the endothelium-dependent vasodilator 5HT as a pharmacological tool. The endothelial dysfunction was sions of 5HT in comparable doses, for endothelial function independent of baseline serum lipid levels. Six weeks of measurement [20, 28] . These beneficial effects of the statins treatment with simvastatin 40 mg did not restore this on endothelial function are most likely explained by the impaired 5HT induced endothelium-dependent vasodilatimprovement of the lipid profiles in these dyslipidemic ion, despite significant lowering of lipid levels.
patients [20, 28] . However, the DM 2 patients in the present The DM 2 patients in this study had a mild study had only a mild dyslipidemia, which probably dyslipidemia, which is characteristic for the disease. All explains the fact that treatment with a relatively high dose patients were free of signs and symptoms of cardiovascular of simvastatin did not change endothelial function in these disease and had no additional cardiovascular risk factors.
patients. This is in agreement with the suggestion that Also autonomic neuropathy was excluded because of the endothelial dysfunction in DM 2 is a consequence of the potential disturbing effects on the vascular wall reactivity. disturbance in glucose metabolism rather than by It is our assumption that this moderately to well regulated, dyslipidemia. The present finding corroborate findings of uncomplicated subset of patients with DM 2, without Sheu et al. [10] , who did not show improvement of additional cardiovascular risk factors are suitable to inendothelial function, using flow mediated vasodilation in vestigate the vascular reactivity, using 5HT and SNP as patients with DM 2 after 24 weeks of treatment with a low pharmacological tools. 5HT is an established substance to dose of simvastatin, 10 mg. We are aware of two studies investigate endothelium-dependent vasodilation in humans, who have recently been completed that also found no and SNP is the gold standard to study endothelium-inimprovement of an impaired endothelial function in padependent vasodilator responses [18, 20] . In the control tients with DM 2 and with multiple other cardiovascular group the vasodilator responses to 5HT and SNP were in risk factors, treated with high dose atorvastatin (F. V. van the same range as found in earlier forearm studies [18,20-Venrooij and R.W. van Etten, personal communications).
22].
This rules out the possibility that only simvastatin is The 5HT-induced forearm vasodilation was significantly unable to restore the endothelial function. impaired among the DM 2 patients, whereas the SNP However, it is remarkable that statins are not beneficial response was intact, showing a selective impaired endofor the endothelial function in DM 2. Since the large thelium-dependent vasodilation in DM 2. This impaired intervention studies showed remarkable and statistically endothelium-dependent vasodilation persisted when only significant beneficial effects of statins, including simvasthe DM 2 patients with normal serum lipids were analysed, tatin, on cardiovascular events in the diabetic subgroup providing evidence that this endothelial dysfunction is not [29] [30] [31] [32] . While the endothelial function has been shown to caused by the mild dyslipidemia, but by the long-term be a predictive tool as evaluated among patients with disturbance in glucose metabolism. In contrast to the manifest cardiovascular disease [2] . This indicates the finding in type 1 DM, in whom Clarkson et al. [23] further need for evaluation of the endothelial function as a showed LDL-cholesterol dependence of the endothelial prognostic marker in patients with DM 2. Other factors function. The present study results are in concordance with could play a role in the development of endothelial the findings in clamp studies in healthy individuals, dysfunction in DM 2, such as the increased oxidative showing that artificially induced high blood glucose levels stress. The inactivation of nitric oxide by oxygen derived or high insulin levels impair endothelial function [3, 4] . radicals could explain the persistent impairment of the Also in patients with type I diabetes endothelial dysfuncendothelial function. More proof for this hypothesis is tion has been associated both with hyperinsulinemia and found in studies showing improvement of the endothelial chronic hyperglycemia [24, 25] . High levels of glucose as function after the administration of antioxidants like well as high levels of insulin can be directly toxic for the vitamin C and folic acid in DM 2 and hypercholesvascular wall. Thereby, high glucose is accompanied by an terolemia [33] [34] [35] . An additional study confirms that preincreased load of oxygen radicals, interfering with the treatment with vitamin C and vitamin E, prevents impairnormal vascular wall function. ment of the, flow mediated, endothelium-dependent vasoAfter 6 weeks of intensive cholesterol lowering treatdilation after oral glucose loading [36] . However, to date ment with simvastatin 40 mg, the impaired 5HT induced antioxidant interventions have not shown beneficial effects endothelium-dependent vasodilation was not restored, deon cardiovascular events [37] [38] [39] . spite a significant improvement of the serum lipid levels
From the large intervention studies evaluating the effects and was not different in subgroups with or without of statins it has been suggested that lipid-independent dyslipidemia. This observation is in sharp contrast with effects of statins explain part of their beneficial effects previous studies in both non-diabetic patients with hy- [40] [41] [42] [43] . Among these pleiotropic effects are anti-thrompercholesterolemia and hypertriglyceridemia where endobogenic, anti-inflammatory and anti-proliferative effects. thelial dysfunction was restored after 4-12 weeks treatHowever, the present study showed no evidence for ment with a HMG-CoA reductase inhibitor, including pleiotropic effects, since simvastatin did not result in simvastatin [11, 20, [26] [27] [28] . In two of these studies the changes of the endothelial function during 6 weeks of same investigational tool was used, i.e. intra-arterial infutreatment. prognostic marker in patients with DM 2.
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